Literature DB >> 27535628

Vertebral Artery Occlusion and Recanalization After Cervical Facet Dislocation.

Zhengfeng Zhang1, Honggang Wang2, Zhiping Mu2.   

Abstract

OBJECTIVE: To investigate clinical features of vertebral artery (VA) occlusion and recanalization after cervical facet dislocation.
METHODS: During a 2-year period from January 2014 to December 2015, 29 consecutive patients with cervical facet dislocation were treated in investigator group. VA occlusion and recanalization were identified retrospectively by magnetic resonance imaging (MRI) at the time of injury and follow-up.
RESULTS: VA occlusion occurred in 6 of the 29 patients (20.7%). All patients were unilateral occlusion and had no vertebrobasilar symptoms. Surgical anterior spinal fusion was performed in 5 patients, and 1 was treated by posterior fusion. Follow-up MRIs revealed VA recanalization in 5 patients. One patient did not undergo MRI because he died of respiratory failure. The time course for VA recanalization was from 6 days after injury to 4 months after operation depending on the length of VA occlusion.
CONCLUSIONS: A fifth of patients with cervical facet dislocation will develop VA occlusion with rare symptomatic vertebrobasilar ischemia. VA recanalization occurs mainly within the first 4 months after injury, regardless of the length of VA occlusion.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical facet dislocation; Magnetic resonance imaging; Occlusion; Recanalization; Vertebral artery

Mesh:

Year:  2016        PMID: 27535628     DOI: 10.1016/j.wneu.2016.08.002

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  1 in total

1.  Early versus delayed reduction of cervical spine dislocation with complete motor paralysis: a multicenter study.

Authors:  Kosei Nagata; Koichi Inokuchi; Hirotaka Chikuda; Keisuke Ishii; Atsuki Kobayashi; Hiroyuki Kanai; Hiroyuki Nakarai; Kota Miyoshi
Journal:  Eur Spine J       Date:  2017-02-28       Impact factor: 3.134

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.